CAJ | 학술논문

血管生成在结直肠癌的发生、发展中发挥重要作用。靶向血管内皮生成因子信号通路的药物治疗晚期结直肠癌获得了重要的生存改善。在化疗基础上联合贝伐珠单抗一线、二线和跨线治疗晚期结直肠癌可进一步延长生存期。阿柏西普联合含伊立替康的化疗方案治疗晚期结直肠癌延长了生存期。对抵抗所有化疗药物的晚期结直肠癌患者使用瑞格非尼后仍延长了生存期。这些抗血管生成药物为晚期结直肠癌患者带来了生存获益，并拥有良好的安全性，可以和化疗药物联合用于晚期结直肠癌患者的的治疗。
혈관생성재결직장암적발생、발전중발휘중요작용。파향혈관내피생성인자신호통로적약물치료만기결직장암획득료중요적생존개선。재화료기출상연합패벌주단항일선、이선화과선치료만기결직장암가진일보연장생존기。아백서보연합함이립체강적화료방안치료만기결직장암연장료생존기。대저항소유화료약물적만기결직장암환자사용서격비니후잉연장료생존기。저사항혈관생성약물위만기결직장암환자대래료생존획익，병옹유량호적안전성，가이화화료약물연합용우만기결직장암환자적적치료。
Angiogenesis plays a vital role in carcinogenesis and development of colorectal cancer. Treatment targeting VEGF signaling pathway acquires important survival prolong for advanced colorectal cancer patients. For advanced colorectal cancer patients,bevacizumab could furtherly prolongs survival time in the setting of first line,second line and continuing therapy after first-progression therapy combined with chemothe-rapy. Aflibercept used in combination with irinotecan-containing regimen improves the survival of advanced colorectal cancer patients in second-line setting. Regorafenib also improves the survival of advanced colorectal cancer patients who have progressed after all line treatment. Considering these suivival benefit and their favora-ble safety,anti-angiogenic agents should be taken into all lines of therapy in the management of advanced colo-rectal cancer.